Find Oncology Drugs in Phase I Clinical Development in SWITZERLAND

Lead Product(s): IOA-244

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: INKEF Capital

Deal Size: $16.5 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 23, 2020

Details:

iOnctura will use the proceeds of the Series A to move its lead molecule IOA-244, a highly selective PI3Kδ-inhibitor, into a Phase I trial in solid tumours and its second program, IOA-289, an ATX-inhibitor, through IND enabling studies.